Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South Korea's ADEL Innovates With Anti-Tau Antibody For Alzheimer’s Disease

Executive Summary

Emerging Company Profile: ADEL Inc. CEO Seung-Yong Yoon tells Scrip how its anti-tau antibody brings something different to the table in the challenging field of Alzheimer's disease and what's in store for the South Korean bioventure.

Advertisement

Related Content

Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis
Interview: AC Immune CEO Reflects On Alzheimer's R&D Post-CREAD
AC Immune/Roche Drop Crenezumab After Phase III CREAD Alzheimer's Failure
Eisai Adds To Alzheimer's Arsenal With Anti-Tau Drug

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124982

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel